Dutton Assoc Announces Investment Opinion: Neoprobe Raised To Strong Speculative Buy Rating By Dutton Assoc
7th Sep 2005, 17:51 GMT
Dutton Assoc continues coverage of Neoprobe Corp, raising its rating to Strong Speculative Buy and setting a revised price target of $1.00.
Latest news from Financial News News from myHealthcareNews.com:
- TRADE NEWS: Agilent Technologies Introduces High-Speed, High-Volume USB Multifunction Data Acquisition Modules, Chassis
- Bio-Rad Closes Buy of Ciphergen Unit
- The LGL Group Reports Q3 Earnings
- Analogic CEO to retire
- Analogic CEO Plans to Retire
- Meade Instruments Contracts with Leading Asian Outsource Manufacturing Firm
- JMAR Receives Nasdaq Delisting Notice
- Analogic Corp Announces Mgmt Changes
- Bio-Rad Purchases Life Science Research Business From Ciphergen Biosystems
- Agilent to buy Switzerland's Acqiris